At the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Graham Jackson, FRCP, FRCPath, MD, of Newcastle University, Newcastle, UK, was selected to present data from the Phase III Myeloma XI trial (NCT01554852) in the oral session. This large-scale exciting trial evaluated the use of lenalidomide maintenance therapy for newly-diagnosed multiple myeloma (MM) patients, who were eligible or ineligible for stem cell transplantation. In this interview, speaking from the meeting, Prof. Jackson provides an overview of the study, its key findings and what they mean.
Myeloma XI trial: lenalidomide maintenance therapy for multiple myeloma
